We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know
Read MoreHide Full Article
CRISPR Therapeutics AG (CRSP - Free Report) closed at $47.69 in the latest trading session, marking a -4.79% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 1.36%. Elsewhere, the Dow lost 1.64%, while the tech-heavy Nasdaq lost 1.46%.
Heading into today, shares of the company had lost 5.79% over the past month, lagging the Medical sector's loss of 5.66% and the S&P 500's loss of 1.76%.
The investment community will be closely monitoring the performance of CRISPR Therapeutics AG in its forthcoming earnings report. In that report, analysts expect CRISPR Therapeutics AG to post earnings of -$1.14 per share. This would mark year-over-year growth of 27.85%. Simultaneously, our latest consensus estimate expects the revenue to be $7.32 million, showing a 741.03% escalation compared to the year-ago quarter.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$4.85 per share and a revenue of $39.15 million, indicating changes of +25.04% and +1015.33%, respectively, from the former year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for CRISPR Therapeutics AG. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.26% higher. As of now, CRISPR Therapeutics AG holds a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 140, placing it within the bottom 43% of over 250 industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know
CRISPR Therapeutics AG (CRSP - Free Report) closed at $47.69 in the latest trading session, marking a -4.79% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 1.36%. Elsewhere, the Dow lost 1.64%, while the tech-heavy Nasdaq lost 1.46%.
Heading into today, shares of the company had lost 5.79% over the past month, lagging the Medical sector's loss of 5.66% and the S&P 500's loss of 1.76%.
The investment community will be closely monitoring the performance of CRISPR Therapeutics AG in its forthcoming earnings report. In that report, analysts expect CRISPR Therapeutics AG to post earnings of -$1.14 per share. This would mark year-over-year growth of 27.85%. Simultaneously, our latest consensus estimate expects the revenue to be $7.32 million, showing a 741.03% escalation compared to the year-ago quarter.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$4.85 per share and a revenue of $39.15 million, indicating changes of +25.04% and +1015.33%, respectively, from the former year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for CRISPR Therapeutics AG. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.26% higher. As of now, CRISPR Therapeutics AG holds a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 140, placing it within the bottom 43% of over 250 industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.